chloroquine and derivatives for COVID-19: living meta-analysis of clinical studies

Table Graph

chloroquine and derivatives - versus potential COVID-19 treatments - for COVID 19 hospitalized pdf xlsx method abbreviations

Outcome	Relative effect 95%CI	Trt. better when	I2	k (RCT/OBS)	Bayesian probability	Overall ROB	Publication bias	Degree of certainty	Endpoint importance	Published MA
efficacy endpoints 00
death D28	1.07 [0.95, 1.21]	< 1	6%	4 studies (4/-)	13.6 %	some concern	not evaluable	moderate	crucial	-
deaths	1.07 [0.97, 1.19]	< 1	0%	28 studies (28/-)	8.7 %	some concern	low	moderate	crucial	-
deaths (time to event analysis only)	1.08 [0.95, 1.23]	< 1	11%	3 studies (3/-)	12.1 %	some concern	not evaluable	moderate	crucial	-
clinical deterioration	1.13 [0.81, 1.60]	< 1	0%	5 studies (5/-)	23.5 %	some concern	not evaluable	moderate	important	-
clinical improvement	1.07 [0.83, 1.39]	> 1	0%	3 studies (3/-)	69.8 %	some concern	not evaluable	moderate	important	-
clinical improvement (14-day)	1.01 [0.78, 1.30]	> 1	0%	4 studies (4/-)	52.1 %	low	not evaluable	high	important	-
clinical improvement (28-day)	0.97 [0.69, 1.37]	> 1	0%	1 study (1/-)	43.2 %	NA	not evaluable		important	-
clinical improvement (7-day)	1.16 [0.84, 1.61]	> 1	0%	1 study (1/-)	81.4 %	NA	not evaluable		important	-
clinical improvement (time to event analysis only)	0.95 [0.80, 1.14]	> 1	0%	4 studies (4/-)	29.6 %	some concern	not evaluable	moderate	important	-
death or ventilation	1.13 [1.03, 1.24]	< 1	0%	5 studies (5/-)	0.5 %	some concern	not evaluable	moderate	important	-
hospital discharge	1.09 [0.82, 1.44]	> 1	43%	5 studies (5/-)	71.8 %	some concern	not evaluable	moderate	important	-
radiologic improvement (14-day)	1.33 [0.94, 1.88]	> 1	0%	1 study (1/-)	94.7 %	NA	not evaluable		important	-
radiologic improvement (7-day)	3.19 [1.16, 8.79]	> 1	0%	2 studies (2/-)	98.7 %	high	not evaluable	low	important	-
viral clearance	0.97 [0.73, 1.29]	> 1	0%	3 studies (3/-)	42.8 %	high	not evaluable	low	important	-
viral clearance (time to event analysis only)	0.85 [0.58, 1.23]	> 1	0%	1 study (1/-)	19.3 %	NA	not evaluable		important	-
viral clearance by day 14	1.09 [0.95, 1.26]	> 1	0%	2 studies (2/-)	88.8 %	some concern	not evaluable	moderate	important	-
viral clearance by day 7	1.20 [0.60, 2.40]	> 1	0%	1 study (1/-)	69.7 %	NA	not evaluable		important	-
ICU admission	1.19 [0.72, 1.96]	< 1	4%	2 studies (2/-)	24.6 %	some concern	not evaluable	moderate	non important	-
off oxygenation	0.98 [0.64, 1.51]	> 1	0%	1 study (1/-)	46.4 %	NA	not evaluable		non important	-
safety endpoints 00
cardiac arrest	1.92 [0.35, 10.49]	< 1	0%	1 study (1/-)	22.7 %	NA	not evaluable		important	-
serious adverse events	1.26 [0.56, 2.84]	< 1	0%	1 study (1/-)	28.7 %	NA	not evaluable		important	-
adverse events	1.57 [1.15, 2.15]	< 1	20%	9 studies (9/-)	0.2 %	some concern	not evaluable	moderate	non important	-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.

chloroquine and derivatives - versus potential COVID-19 treatments - for COVID 19 hospitalized pdf xlsx method abbreviations

efficacy endpoints 00

safety endpoints 00